Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants
Eligible age
30–70 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Our goal of the study is to learn the effects of the diabetes medication named Pioglitazone, in type-2 diabetic obese participants with Heart failure. The main question it aims to answer are: 1. To demonstrate that impaired mitochondrial function leading to reduced ATP generation plays a key pathophysiologic role in the development of heart failure with preserved ejection fraction (HFpEF) in obese type 2 diabetic (T2D) individuals. 2. To demonstrate that pioglitazone, improves diastolic (as well as systolic) function by improving myocardial insulin sensitivity and by reducing both myocardial and epicardial fat content.
Sponsor: The University of Texas Health Science Center at San Antonio
You may qualify if…
- ✓ 1. Provision of signed and dated informed consent form
- ✓ 2. Stated willingness to comply with all study procedures and availability for the duration of the study
- ✓ 3. Male or female, aged 30-70 years
- ✓ 4. Body Mass Index (BMI) of 27.5-40kg/m²
- ✓ 5. HbA1c of 6.5 to 10%
- ✓ 6. Blood pressure of less than or equal to 145/65mmHg
- ✓ 7. eGFR greater than 45 ml/min/1.73m²
- ✓ 8. Subject must have HFpEF (EF \> 50% by ECHO screening)
You may not qualify if…
- ✕ 1. Subjects with history of osteoporosis or proliferative diabetic retinopathy
- ✕ 2. Subjects with Heart failure due to restrictive or infiltrative cardiomyopathy, active myocarditis, constrictive pericarditis, severe valvular heart disease, etc. will be excluded
- ✕ 3. Patients with symptomatic coronary artery disease.
- ✕ 4. Subjects with significant change in diuretic management during the month prior to screening (defined by doubling of diuretic dose, or addition of another HF medication).
- ✕ 5. Subjects treated with a GLP-1 RA or thiazolidinedione.
- ✕ 6. Subjects treated with a SGLT2i
- ✕ 7. Pregnancy or lactation
- ✕ 8. Known allergic reactions to components of the study interventions.
Where it's recruiting
San Antonio
Source: ClinicalTrials.gov · NCT05838287 · last updated 2025-08-27